Literature DB >> 23864485

A new mathematical pharmacodynamic model of clonogenic cancer cell death by doxorubicin.

Jan Lankelma1, Rafael Fernández Luque, Henk Dekker, Jaap van den Berg, Bob Kooi.   

Abstract

Previous models for predicting tumor cell growth are mostly based on measurements of total cell numbers. The purpose of this paper is to provide a new simple mathematical model for calculating tumor cell growth focusing on the fraction of cells that is clonogenic. The non-clonogenic cells are considered to be relatively harmless. We performed a number of different types of experiments: a long-term drug "treatment", several concentrations/fixed time experiments and time-series experiments, in which human MCF-7 breast cancer cells were exposed to doxorubicin and the total number of cells were counted. In the latter two types, at every measurement point a plating efficiency experiment was started. The final number of colonies formed is equal to the number of clonogenic cells at the onset of the experiment. Based on the intracellular drug concentration, our model predicts cell culture effects taking clonogenic ability and growth inhibition by neighboring cells into account. The model fitted well to the experimental data. The estimated damage parameter which represents the chance of an MCF-7 cell to become non-clonogenic per unit time and per unit intracellular doxorubicin concentration was found to be 0.0025 ± 0.0008 (mean ± SD) nM(-1) h(-1). The model could be used to calculate the effect of every doxorubicin concentration versus time (C-t) profile. Although in vivo parameters may well be different from those found in vitro, the model can be used to predict trends, e.g. by comparing effects of different in vivo C-t profiles.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23864485     DOI: 10.1007/s10928-013-9326-0

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  31 in total

1.  Modeling of the time-dependency of in vitro drug cytotoxicity and resistance.

Authors:  L M Levasseur; H K Slocum; Y M Rustum; W R Greco
Journal:  Cancer Res       Date:  1998-12-15       Impact factor: 12.701

2.  Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics.

Authors:  Y N Sun; W J Jusko
Journal:  J Pharm Sci       Date:  1998-06       Impact factor: 3.534

3.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents.

Authors:  W J Jusko
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

4.  A Gompertzian model of human breast cancer growth.

Authors:  L Norton
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

5.  Doxorubicin gradients in human breast cancer.

Authors:  J Lankelma; H Dekker; F R Luque; S Luykx; K Hoekman; P van der Valk; P J van Diest; H M Pinedo
Journal:  Clin Cancer Res       Date:  1999-07       Impact factor: 12.531

Review 6.  Tissue transport of anti-cancer drugs.

Authors:  Jan Lankelma
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

Review 7.  Hallmarks of senescence in carcinogenesis and cancer therapy.

Authors:  Jerry W Shay; Igor B Roninson
Journal:  Oncogene       Date:  2004-04-12       Impact factor: 9.867

Review 8.  Drug delivery and transport to solid tumors.

Authors:  Seong Hoon Jang; M Guillaume Wientjes; Dan Lu; Jessie L S Au
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

9.  Simulation model of doxorubicin activity in islets of human breast cancer cells.

Authors:  Jan Lankelma; Rafael Fernández Luque; Henk Dekker; Herbert M Pinedo
Journal:  Biochim Biophys Acta       Date:  2003-08-22

10.  Chemosensitivity testing of small cell lung cancer using the MTT assay.

Authors:  B G Campling; J Pym; H M Baker; S P Cole; Y M Lam
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

View more
  4 in total

1.  Three model shapes of Doxorubicin for liposome encapsulation.

Authors:  Kanes Sumetpipat; Duangkamon Baowan
Journal:  J Mol Model       Date:  2014-11-06       Impact factor: 1.810

Review 2.  Modeling cancer metabolism on a genome scale.

Authors:  Keren Yizhak; Barbara Chaneton; Eyal Gottlieb; Eytan Ruppin
Journal:  Mol Syst Biol       Date:  2015-06-30       Impact factor: 11.429

3.  Leveraging Mathematical Modeling to Quantify Pharmacokinetic and Pharmacodynamic Pathways: Equivalent Dose Metric.

Authors:  Matthew T McKenna; Jared A Weis; Vito Quaranta; Thomas E Yankeelov
Journal:  Front Physiol       Date:  2019-05-22       Impact factor: 4.566

4.  A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast Cancer.

Authors:  Matthew T McKenna; Jared A Weis; Stephanie L Barnes; Darren R Tyson; Michael I Miga; Vito Quaranta; Thomas E Yankeelov
Journal:  Sci Rep       Date:  2017-07-18       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.